LHX6 and cervical cancer: More importantly, our results indicated that LHX6EX(+12) isoform group was the dominant constituent and oncogenic type of LHX6 in cervical cancer, supporting its potentials as a new biomarker and a precise therapeutic target for cervical cancer in the future by managing the oncogenic LHX6 isoforms.